Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New trends in antimicrobial development

E L Setti1, R G Micetich

  • 1Medicinal Chemistry Division, SynPhar Laboratories Inc., #2 4290-91 St., Edmonton, Alta. T6E 5V2, Canada.

Current Medicinal Chemistry
|July 1, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

(1)H-NMR and NOE studies of 2-cephems and 3-cephems.

Archives of pharmacal research·2008
Same author

Monobactams as enzyme inhibitors.

IDrugs : the investigational drugs journal·2005
Same author

4-oxa-1-azabicyclo[3.2.0]heptan-7-one derivatives as anti-tumor agents.

Current medicinal chemistry. Anti-cancer agents·2003
Same author

In vitro and in vivo activities of syn2836, syn2869, syn2903, and syn2921: new series of triazole antifungal agents.

Antimicrobial agents and chemotherapy·2001
Same author

Practical aspects of liquid chromatography/electrospray tandem mass spectrometry for rapid identification of metabolites of a new antifungal agent SYN-2836 in dog urine.

Rapid communications in mass spectrometry : RCM·2001
Same author

New trends in antimicrobial development.

EXS·2000
Same journal

Knockdown of circFGFR2 inhibits prostate cancer cell metastasis and proliferation by targeting miR-221-5p/ SMUG1 pathway.....

Current medicinal chemistry·2026
Same journal

LncRNA signature associated with amino acid metabolism: A novel prognostic tool for Clear Cell Renal Cell Carcinoma.

Current medicinal chemistry·2026
Same journal

HRI Kinase Modulation by BTdCPU as a Therapeutic Strategy for Bortezomib Resistance in Prostate Cancer.

Current medicinal chemistry·2026
Same journal

EGFR Dysregulation in Cancer: From Molecular Mechanisms and Key Mutations to Evolving TKI Strategies and Resistance Mitigation.

Current medicinal chemistry·2026
Same journal

DHRS2 as a Novel Thalidomide Target Regulating Mitophagy and Inflammation in Head and Neck Squamous Cell Carcinoma.

Current medicinal chemistry·2026
Same journal

Synthetic AtMP2 from Anabas testudineus: Comprehensive ADMET and In Vivo Toxicity Assessment to Enable Future Therapeutic Development.

Current medicinal chemistry·2026
See all related articles

Microbial resistance to antibiotics is a growing threat. New strategies focus on improving existing drugs and discovering novel antimicrobial agents with unique mechanisms of action.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Drug Discovery

Background:

  • Antibiotic resistance in microbes is a significant global health challenge.
  • Traditional antibacterial therapies are becoming less effective against resistant pathogens.
  • The need for novel anti-infective agents is critical.

Purpose of the Study:

  • To review current approaches for discovering new antimicrobial agents.
  • To highlight strategies for overcoming microbial resistance to antibiotics.
  • To present recent advancements in antimicrobial discovery.

Main Methods:

  • Review of scientific literature on antimicrobial resistance and drug discovery.
  • Analysis of two primary strategies: improving existing antimicrobials and seeking novel agents.

Related Experiment Videos

  • Synthesis of latest findings in the field.

    • Main Results:

    • Two main strategies are employed: enhancing classical antimicrobials and searching for novel agents with new mechanisms.
    • Targeting resistance factors is a key approach for improving existing drugs.
    • Discovery of new agents with novel modes of action offers a path forward.

    Conclusions:

    • Addressing microbial resistance requires a dual approach.
    • Continuous innovation in antimicrobial discovery is essential to combat evolving pathogens.
    • Further research into novel anti-infective agents is crucial for public health.